CLUSTER
31.7.2024 18:01:27 CEST | Business Wire | Press release
Cluster, Inc, the largest metaverse platform in Japan with over 35 million event participants, collaborated with Associate Professor Hasei of the Department of Medical Information and Assistive Technology Development, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences (Department of Orthopedics) to realize a virtual space to help alleviate the sense of loneliness among patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240731328522/en/
Exchange between patients with the same disease (Graphic: Business Wire)
This initiative is a collaboration between Cluster, Inc. and Associate Professor Hasei, marking the world’s first use of the metaverse in alleviating the loneliness for rare cancer patients, particularly pediatric and adolescent young adults (AYA). This project aims to create a virtual space to allow cancer patients with conditions like osteosarcoma to interact and share experiences with other patients who have the same condition and age group.
Yearly, there are 20,000 rare cancer patients in pediatrics and AYA. Associate Professor Hasei thought interactions and communication between patients with the same disease would help improve their quality of life. The metaverse platform enables them to connect from different locations, enjoy games, share their experiences, and find emotional support despite their physical conditions. This approach showed promising results for children and AYA patients, who find it difficult to meet peers with the same experiences, especially those with extremely rare conditions like Ewing sarcoma, thereby enabling improvement in their mood and boosting social interaction for isolated individuals.
Cultural celebrations such as the virtual Tanabata Festival allowed hospitalized children to experience and enjoy the virtual worlds beyond their hospital rooms. These experiences brought smiles to patients, even for those who rarely do. This shows the potential of the metaverse to deliver meaningful experiences beyond physical boundaries.
Associate Professor Hasei realized that for this project to be as effective as possible, technological challenges and critical functions needed to be carefully considered. Cluster's expertise in this field made it possible for this project to succeed. Moving forward, our team hopes to further explore and create metaverse applications in medicine, using its ability to address social issues and enhance human creativity beyond physical limitations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731328522/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CAIRDAC Adds Operational Expertise to Its Board of Directors With the Appointment of Rinda Sama9.11.2026 13:44:00 CET | Press release
CAIRDAC, SA, a pre-revenue-stage medtech company developing ALPS™, a leadless, self-powered cardiac pacing system, today announced the appointment of Mr. Rinda Sama to its Board of Directors. His appointment adds deep manufacturing, quality and operational experience to the Board and follows the recent appointment of Raymond W. Cohen as Chairman. “Mr. Sama’s extensive experience in manufacturing, quality systems and operational scale-up for complex implantable devices will be extremely valuable to our Company as we prepare for clinical evaluation and the next stages of development,” said Edouard Fonck, Chief Executive Officer of CAIRDAC. Mr. Sama currently serves as CEO of Spiro Medical, a company focused on treating asthma employing a proprietary neuromodulation system. He previously served as Chief Operating Officer of publicly traded Axonics, Inc. where he was accountable for manufacturing and quality and the operational infrastructure that supported the company’s commercial growth.
Nominations Open for Sixth Edition of Aster Guardians Global Nursing Award 2027 Worth USD 250,000 Prize9.11.2026 13:35:00 CET | Press release
Aster DM Healthcare has announced the launch of the sixth edition of the Aster Guardians Global Nursing Award, inviting registered nurses worldwide to showcase their contributions to healthcare and compete for a prize of USD 250,000. The award recognises nurses whose work advances patient care, strengthens healthcare systems, drives innovation and transforms communities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109180902/en/ Aster Guardians Global Nursing Award - One nurse will win the trophy and the prize of USD 250,000 (Photo: AETOSWire) Open to registered nurses worldwide, the award recognises contributions across five areas: Patient Care, Nursing Education, Social and Community Service, Research and Innovation, and Nursing Leadership and Administration. Applicants can share their professional journeys through case-study questions, in multiple languages at www.asterguardians.com until December 31, 2026. The 2026
Datavault AI and Biochar Now Combine Insured Carbon Removal Credits with Patented Tokenization Technology9.11.2026 12:45:00 CET | Press release
Datavault AI Inc. (“Datavault” or the “Company”) (Nasdaq: DVLT), today announced a global strategic collaboration with Biochar Now to expand the distribution of verified, insured carbon removal credits through Datavault’s patented tokenization technology and global marketing and distribution capabilities. The partnership is designed to connect Biochar Now’s carbon removal credits with a broader network of buyers while strengthening transparency, traceability and accountability in the carbon markets. Under the agreement, Datavault AI will provide access to its carbon credit tokenization technology, including U.S. Patent No. 12,443,977 and related pending applications. It will also support worldwide demand generation, buyer development, marketing and distribution of eligible Biochar Now carbon credits, while also pursuing listings with existing and future partner exchange platforms. Biochar Now will pay Datavault AI for its technology and services; specific financial terms were not discl
NIQ to Present at 2026 J.P. Morgan Ultimate Services Investor Conference9.11.2026 12:45:00 CET | Press release
NielsenIQ (NYSE: NIQ) (the “Company”, or “NIQ”), a leading global consumer intelligence company, today announced that Jim Peck, Chairman and CEO, and Mike Burwell, CFO will participate in a fireside chat at the J.P. Morgan Ultimate Services Investor Conference on Tuesday, November 17, 2026 at 2:40 pm ET. A live webcast will be available on the NIQ investor relations website at https://investors.nielseniq.com. A replay will also be available on the Company's website following the conclusion of the presentation. About NielsenIQ NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior. Combining an unmatched global data footprint, granular consumer and retail measurement, and decades of AI modeling expertise, NIQ helps companies turn complex data into confident action. With operations in more than 90 countries covering approximately 82% of the world’s population and more than $7.4 trillion in consumer spend, N
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression9.11.2026 12:30:00 CET | Press release
Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000 participants living with highly chronic TRD Deep commercial capabilities in place to enable successful launch execution and broad patient access with launch readiness on track for expected launch in H12027, subject to FDA approval Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). "People living with treatment-resistant depression have gone too long experiencing disproportionate suffering, despite years of trying available treatment options without meaningful relief. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom